Get started
Sinopharm Group Co., Ltd. Class HSinopharm Group Co., Ltd. Class HSinopharm Group Co., Ltd. Class H

Sinopharm Group Co., Ltd. Class H

No trades
See on Supercharts
Overview
Financials News Discussions Forecast Seasonals

X2S chart


Full chart

X2S upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪6.40 B‬ EUR
Dividend yield (indicated)
3.96%
Price to earnings Ratio (TTM)
8.0070
Basic EPS (TTM)
0.2545 EUR
Net income (FY)
‪950.09 M‬ EUR
Revenue (FY)
‪78.77 B‬ EUR
Shares float
‪1.34 B‬
Beta (1Y)
0.79

Employees


Employees (FY)
‪108.22 K‬
Change (1Y)
‪−7.74 K‬ −6.68%
Revenue / Employee (1Y)
—
Net income / Employee (1Y)
—

About Sinopharm Group Co., Ltd. Class H


Sector
Distribution Services
Industry
Medical Distributors
Website
ir.sinopharmgroup.com.cn
Headquarters
Shanghai
Founded
2003
ISIN
CNE100000FN7
FIGI
BBG000VZC5T1
Sinopharm Group Co., Ltd. is a distributor of pharmaceutical and healthcare products and a value added supply chain service provider in the People's Republic of China. It operates through the following business segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment provides distribution, logistics and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers and other suppliers. The Medical Devices segment consists of the distribution of medical devices in China. The Retail Pharmacy segment refers to the network of retail drug stores in major cities of China via direct operations and franchises. The Other Business segment comprises of the production and sale of pharmaceutical products, chemical reagents and laboratory supplies. The company was founded on January 8, 2003 and is headquartered in Shanghai, China.

Check out other big names from the same industry as X2S.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

X2S news



Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Sparks


Curated watchlists where X2S is featured.

See all sparks 

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on SWB exchange Sinopharm Group Co., Ltd. Class H stocks are traded under the ticker X2S.
We've gathered analysts' opinions on Sinopharm Group Co., Ltd. Class H future price: according to them, X2S price has a max estimate of 2.72 EUR and a min estimate of 1.90 EUR. Watch X2S chart and read a more detailed Sinopharm Group Co., Ltd. Class H stock forecast: see what analysts think of Sinopharm Group Co., Ltd. Class H and suggest that you do with its stocks.
X2S reached its all-time high on Aug 12, 2016 with the price of 4.8370 EUR, and its all-time low was 1.5000 EUR and was reached on Aug 23, 2011. View more price dynamics on X2S chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Sinopharm Group Co., Ltd. Class H financials in yearly and quarterly reports right on TradingView.
Sinopharm Group Co., Ltd. Class H is going to release the next earnings report on Mar 20, 2026. Keep track of upcoming events with our Earnings Calendar.
X2S earnings for the last half-year are 0.13 EUR per share, whereas the estimation was 0.11 EUR, resulting in a 14.43% surprise. The estimated earnings for the next half-year are 0.13 EUR per share. See more details about Sinopharm Group Co., Ltd. Class H earnings.
Sinopharm Group Co., Ltd. Class H revenue for the last half-year amounts to ‪33.89 B‬ EUR, despite the estimated figure of ‪34.41 B‬ EUR. In the next half-year revenue is expected to reach ‪34.11 B‬ EUR.
X2S net income for the last half-year is ‪402.45 M‬ EUR, while the previous report showed ‪451.16 M‬ EUR of net income which accounts for −10.80% change. Track more Sinopharm Group Co., Ltd. Class H financial stats to get the full picture.
Yes, X2S dividends are paid annually. The last dividend per share was 0.08 EUR. As of today, Dividend Yield (TTM)% is 3.96%. Tracking Sinopharm Group Co., Ltd. Class H dividends might help you take more informed decisions.
Sinopharm Group Co., Ltd. Class H dividend yield was 3.47% in 2024, and payout ratio reached 30.17%. The year before the numbers were 4.67% and 29.82% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Sep 1, 2025, the company has ‪108.22 K‬ employees. See our rating of the largest employees — is Sinopharm Group Co., Ltd. Class H on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Sinopharm Group Co., Ltd. Class H EBITDA is ‪2.63 B‬ EUR, and current EBITDA margin is 3.77%. See more stats in Sinopharm Group Co., Ltd. Class H financial statements.
Like other stocks, X2S shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Sinopharm Group Co., Ltd. Class H stock right from TradingView charts — choose your broker and connect to your account.